Oncopharmpod
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:12:25
- Mas informaciones
Informações:
Sinopsis
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
